Inovio’s HPV Immunotherapy Moves to Phase III, Stock Rises – Zacks.com
TheStreet.com |
Inovio's HPV Immunotherapy Moves to Phase III, Stock Rises
Zacks.com Inovio Pharmaceuticals, Inc's (INO – Free Report) shares rose over 10% after the company initiated a pivotal phase III REVEAL study to evaluate the safety and efficacy of immunotherapy, VGX-3100 to treat cervical dysplasia caused by human … Inovio Begins Phase 3 Clinical Trial Of VGX-3100 For The Treatment Of HPV-Related Cervical Pre-Cancer FDA lifts clinical hold on HPV vaccine trial |
